Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Takeda
Biotech
Protagonist prefers $400M from Takeda over rusfertide US profits
While the FDA mulls whether to approve Protagonist’s hematology asset, the biopharma is planning to pocket $400 million rather than split profits.
James Waldron
Feb 26, 2026 10:00am
Angelini nocks an AI arrow with $120M Quiver deal
Feb 23, 2026 11:04am
Takeda consolidates Boston footprint
Feb 11, 2026 3:51pm
New rules, higher stakes: Biopharma plays the long game in 2026
Jan 26, 2026 2:40pm
Takeda leader says AI gave early-stage asset a 'phoenix' rebirth
Jan 13, 2026 6:16am
Takeda looks to 2026 FDA filing for Sotyktu rival zasocitinib
Dec 18, 2025 7:55am
